Page last updated: 2024-10-24

cefixime and HbS Disease

cefixime has been researched along with HbS Disease in 2 studies

Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.

Research Excerpts

ExcerptRelevanceReference
" One child developed bacteremia 3 days after completing the course of cefixime, and one had splenic sequestration on the fourth study day."5.08Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. ( Dancy, RM; Day, SW; Harris, SC; Wang, WC; Wilimas, JA; Williams, LL, 1996)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Mohzari, YA1
Alshuraim, R1
Asdaq, SMB1
Aljobair, F1
Alrashed, A1
Alsowaida, YS1
Alamer, A2
Al Munjem, MF1
Al Musawa, MI1
Hatata, M1
Alzaaqi, MA1
Binrokan, A1
Alajlan, SA1
Abraham, I1
Williams, LL1
Wilimas, JA1
Harris, SC1
Day, SW1
Dancy, RM1
Wang, WC1

Trials

1 trial available for cefixime and HbS Disease

ArticleYear
Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease.
    Journal of pediatric hematology/oncology, 1996, Volume: 18, Issue:3

    Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Anti-Infective Agents; Bacteremia; Bacterial

1996

Other Studies

1 other study available for cefixime and HbS Disease

ArticleYear
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis.
    Journal of infection and public health, 2022, Volume: 15, Issue:1

    Topics: Anemia, Sickle Cell; Anti-Bacterial Agents; Cefixime; Child; Humans; Male; Osteomyelitis; Prospectiv

2022